TOKYO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan, SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore) (TSE:4592), today announced it is one of the founding member organizations of the National TBI Registry Coalition (NTRC) in the United States.

The NTRC announced its official launch on December 6, 2021 and was formed to align several leading nonprofit and corporate organizations dedicated to working with the U.S. government to create a national registry for individuals living with a traumatic brain injury (TBI). Once created, the registry will assist individuals and families with surveillance and prevention opportunities as well as provide easily accessible information about new therapies and services to address TBI. Additionally, NTRC member organizations are working together to promote public awareness about individuals and caregivers impacted by TBI. The NTRC website can be accessed at www.nationaltbiregistry.org.

�We believe a national TBI registry is critically important to improve surveillance, increase awareness, and provide support to individuals living with a traumatic brain injury, and we are proud to be one of the founding members of the NTRC,� said Keita Mori, Chairman of SanBio and Secretary of the NTRC Steering Committee. �Joining this coalition with like-minded organizations is another step towards potentially improving the lives of individuals suffering from complications resulting from a traumatic brain injury. In addition, we continue to publish important research relevant to the field, and we are currently preparing to file a Biologics License Application for potential approval in Japan for our lead asset, SB623, for the treatment of chronic motor deficits resulting from TBI.�

About Traumatic Brain Injury

Traumatic brain injury (TBI) is defined by the U.S. Centers for Disease Control and Prevention as any bump or blow to the head, or penetrating injury, that results in the disruption of normal brain function, and is one of the leading causes of death and disability worldwide. The estimated global incidence of acute TBI during 2016 was 27 million cases, and the estimated global prevalence of chronic impairment secondary to TBI was 55.5 million cases.¹ In the United States, approximately 43% of surviving hospitalized persons with TBI experience long-term disabilities², and it is estimated that 3.17 million people are living with long-term disabilities secondary to TBI.³ Overall, TBI and long-term motor deficits secondary to TBI significantly impair a person�s self-care, employability, and quality of life, and are major burdens on healthcare systems worldwide.

About SB623

SB623 is a proprietary, cell-based investigational product made from allogeneic modified and cultured adult bone marrow-derived mesenchymal stem cells (MSCs) that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brain�s natural regenerative ability to recover lost motor functions. SanBio is preparing to file a Biologics License Application with the Pharmaceuticals and Medical Devices Agency in Japan for SB623 for the treatment of chronic motor deficits resulting from TBI.

About SanBio Group (SanBio Co., Ltd., SanBio, Inc. and SanBio Asia Pte. Ltd.)

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company�s propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and stroke. The Company is headquartered in Tokyo, Japan, Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore), and additional information about SanBio Group is available at https://sanbio.com/en/

�

Contacts

For more information, contact:
SanBio Co., Ltd.

Management Administration

Yoshihiro Kakutani

[email protected]